Business Context and Reporting Period
Company: Tempest Therapeutics, Inc. (TPST)
Filing Type: Form 8-K (Current Report)
Report Date: May 14, 2026
Reporting Period: Quarter ended March 31, 2026
Context: The filing serves to announce financial results and business highlights for the first quarter of 2026 via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release containing the specific financial data but does not include the numerical values within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. It only indicates that such results were announced in the referenced press release.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release on May 14, 2026, detailing results and business highlights. Specific commentary, guidance, or outlook is contained within Exhibit 99.1 and is not present in the main body of this 8-K text.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 14, 2026) for actual revenue, net loss, and cash position figures.
- Verify the specific "business highlights" mentioned in the press release to understand operational progress.
- Check for any forward-looking statements or updated guidance included in the press release.
- Confirm the company's cash runway and burn rate, as these are critical for a pre-revenue or early-stage biotech firm like Tempest Therapeutics.